环氧合酶-2 抑制剂防治阿尔茨海默氏病的进展

中国临床药理学与治疗学 ›› 2003, Vol. 8 ›› Issue (3): 249-251.

环氧合酶-2 抑制剂防治阿尔茨海默氏病的进展

苏湲淇, 董志

重庆医科大学药理学教研室, 重庆 400016

收稿日期:2003-01-23 修回日期:2003-02-20 出版日期:2003-06-26 发布日期:2020-11-25
通讯作者: 董志, 男, 博士, 教授, 硕士生导师, 副校长, 从事神经药理学研究。Tel:13508393231 E-mail:zhidong073@hotmail.com
作者简介:苏湲淇, 女, 硕士研究生, 神经药理学专业。

Progress of cyclooxygense-2 inhibitors in treatment of Alzheimer' s disease

SU Yuan-Qi, DONG Zhi

Department of Pharmacology, Chongqing Medical University, Chongqing, 400016

Received:2003-01-23 Revised:2003-02-20 Online:2003-06-26 Published:2020-11-25

摘要/Abstract

摘要： 阿尔茨海默氏病(Alzheimer' s disease, AD) 是最常见的一种老年期痴呆综合症, 它的发生与炎症密切相关。炎症过程在阿尔茨海默氏病的退行性变和认知功能障碍的发病机理中起了关键性的作用。据报道, 环氧合酶-2(COX-2) 抑制剂在延缓AD 病的进程和改善认知能力上是很有效的。该领域的研究对于探讨AD 病的发病机制以及研究其防治措施均有重要意义。

关键词: 药理学, 综述, 环氧合酶-2 抑制剂, 非甾体消炎药, 阿尔茨海默氏病

Abstract: Alzheimer' s disease (AD) is the most common cause of dementia in the elderly population.The occurrence of dementia correlates with inflammation.Inflammation processes may play a critical role in the pathogenesis of the degenerative changes and cognitive impairments associated with Alzheimer' s disease.Cyclooxygense- 2 (COX-2) inhibitors are reported to be effective in reducing the risk of developing AD or cognitive impairments.Studies on this field are of important significance in the understanding the pathogenesis and therapeutic measures for AD.This review will discuss the progress in the treatment of Alzheimer' s disease by COX-2 inhibitors.

Key words: pharmacology, review, cyclooxygense-2 inhibitors, nonsteroidal anti-inflammatory drugs, Alzheimer's disease

中图分类号:

R971.1
R743

苏湲淇, 董志. 环氧合酶-2 抑制剂防治阿尔茨海默氏病的进展[J]. 中国临床药理学与治疗学, 2003, 8(3): 249-251.

SU Yuan-Qi, DONG Zhi. Progress of cyclooxygense-2 inhibitors in treatment of Alzheimer' s disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 249-251.

参考文献

[1] Halliday G, Robinson SR, Shepherd C, et al.Alzheimer's disease and inflammtion:a review of cellular and therapeutic mechanisms[J]. Clin Exp Pharmacolo Physiol, 2000;27: 1-8
[2] 杨文明, 李泽庚, 周宜轩, 等.老年性痴呆病因及药物治疗[J]. 医学综述, 2002; 8:170-2
[3] Rogers J, Kirby LC, Hempelman SR, et al.Clinical trial of indomethacin in Alzheimer's disease[J]. Neurology, 1993; 43: 1609-11
[4] Bernd LF, Barbara M, Martina B, et al.Interleukin-1β induces cyclooxygenase-2 and prostaglandin E2 synthesis in human neuroblastoma cells[J]. J Neurochem, 2000;75:2020-8
[5] Wollhim FA.New function for Cox-2 in health and disease[J]. Arthritis Res, 1999; 1:45-9
[6] Raymond ND, Steven BA, Leslie C, et al.Cyclooxygenase in biology and disease[J]. FASEB J, 1998;12:1063-73
[7] Vane JR, Botting RM.Mechanism of action of nonsteroidal antiinflammatory drugs[J]. AM JMed, 1998;104: 2-8
[8] Vane J.Aspirin and other anti-inflammatory drugs[J]. Thorax, 2000; 55:3-9
[9] Aisen PS.Evaluation of selective cox-2 inhibitors for the treatment of Alzheimer's disease[J]. J Pain Symptom Manage, 2002;23:35-40
[10] Issam AM, Garret AF.Selective inhibitors of cyclooxygenase-2[J]. Mol Interventions, 2001;1:30-8
[11] Barner A.Review of clinical trials and benefit risk ratio of meloxicam[J]. Scand J Rheumatol (Suppl), 1996;102:29-31
[12] Aisen PS, Schmeidler J, Pasinetti GM, et al.Randomized pilot study of nimesulide treatment in Alzheimer's disease[J]. Neurology, 2002; 58:1050-4
[13] Hawkey CJ.COX-2 inhibitors[J]. Lancet, 1999;353: 307-14
[14] Ferencik M, Novak M, Rovensky J, et al.Alzheimer's disease, inflammation and non-steroidal anti- inflammatory drugs[J]. Bratisl Lek Lisky, 2001;102: 123-32
[15] Ehrich EW, Dallob A, Lepeleire ID, et al.Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental model[J]. Clin Pharmacol Ther, 1999; 65:336-47